Avanza Fonder’s Verona Pharma VRNA Stock Holding History

Avanza Fonder’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,737	Closed	-$164K	–	435
2025 Q2	$164K	Buy	1,737 +86	+5%	+$6.37K	﹤0.01%	395
2025 Q1	$99.5K	Buy	+1,651	New	+$98.8K	﹤0.01%	438

Other funds holding VRNA

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Avanza Fonder's VRNA Position: Q3 2025 in Review

Avanza Fonder sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 1,737 shares — an estimated $164K sold.

Avanza Fonder first reported a position in VRNA in Q1 2025 and held it in 2 quarters. The position peaked at $164K in Q2 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

Avanza Fonder reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
Avanza Fonder sold 1,737 Verona Pharma shares in Q3 2025, an estimated $164K.
Avanza Fonder first reported a position in Verona Pharma in Q1 2025 and held it in 2 quarters.
Avanza Fonder's Verona Pharma position peaked at $164K in Q2 2025.
243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Avanza Fonder's 13F filing for Q3 2025, filed 16 Oct 2025.